Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.

Published: Nov 03, 2009

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009. Dr. Hampl, also named as Executive Chairman of the Board, succeeds current Chairman Dr. Ulf M. Schneider. Dr. Schneider will continue to serve on the Board of Directors and as a member of the Audit Committee.

Back to news